X
- No products in the list
The DPYD PharmaKitDx™ provides a reliable solution for the detection of clinically relevant variants in the DPYD gene using real-time PCR. The assay enables identification van key DPYD alleles associated with reduced dihydropyrimidine dehydrogenase (DPD) activity, supporting pharmacogenomic analysis of fluoropyrimidine metabolism.
The kit includes multiple targets within a multiplex workflow and is optimized for reproducible detection of variants linked to altered drug response. It supports molecular biology applications focused on pharmacogenomics and treatment-related toxicity risk.
Note that this kit is for Research Use Only (RUO).
This test is also available as a Stripassay 5FU DPYD (PGX-5FU XL) from our esteemed partner Viennalab.
The DPYD gene encodes the enzyme dihydropyrimidine dehydrogenase (DPD), which is responsible for the metabolism of fluoropyrimidine drugs such as 5-fluorouracil (5-FU) and capecitabine. These agents are widely used in the treatment of various cancers, including colorectal, breast, and gastrointestinal malignancies.
DPD plays a key role in the catabolism of these drugs, and reduced or absent enzyme activity can lead to the accumulation of toxic metabolites. Genetic variants in the DPYD gene are associated with decreased DPD activity and an increased risk of severe adverse reactions to fluoropyrimidine-based therapies.
Identification of DPYD variants is therefore critical in pharmacogenomic research focused on drug metabolism, toxicity risk, and variability in treatment response.
The DPYD PharmaKitDx™ is designed for the qualitative detection of key DPYD variants using real-time PCR technology. The assay targets clinically relevant alleles associated with reduced enzyme activity, including DPYD2A, DPYD13, DPYD hapB3, and c.2846A>T (D949V).
The workflow consists of multiplex PCR reactions that enable simultaneous analysis of multiple variants within a limited number of steps. This design supports efficient processing and reduces variability between runs.
The assay requires a low input of genomic DNA and is compatible with DNA extracted from peripheral blood samples, making it suitable for routine molecular workflows.
The assay design supports reliable detection of DPYD variants through optimized primer and probe configurations. The multiplex format allows consistent amplification across targets, ensuring reproducible results.
Standardized reaction conditions and compatibility with commonly used real-time PCR platforms contribute to consistent assay performance across different laboratory environments.
The kit is designed for integration into standard real-time PCR workflows. With a short hands-on time and defined PCR runtime, the assay supports efficient sample processing in laboratories performing pharmacogenomic analysis.
The assay is compatible with real-time PCR cyclers equipped with standard fluorescence detection channels, enabling straightforward implementation without specialized instrumentation.
Detection of DPYD variants supports research into pharmacogenomics and drug metabolism, particularly in the context of fluoropyrimidine-based therapies. Identification of these variants enables investigation of genetic factors influencing drug toxicity and treatment response.
The assay can be used in studies exploring genotype-based stratification, adverse drug reactions, and variability in metabolic capacity. It also supports research into personalized medicine approaches, where genetic information is used to guide therapeutic strategies.
In addition, DPYD genotyping contributes to broader research on enzyme deficiency, metabolic pathways, and interindividual variability in drug response.
The DPYD PharmaKitDx™ provides a targeted, real-time PCR-based solution for the detection of clinically relevant DPYD variants. Its multiplex design, low DNA input requirement, and compatibility with standard laboratory equipment enable accurate and reproducible analysis.
Optimized for integration into molecular workflows, the kit supports research into pharmacogenomics, drug metabolism, and genetic determinants of treatment-related toxicity.